GET DAILY SIGNALSAmarin Corporation (AMRN) Returns to Profitability in Q3 2026 as Restructuring Takes Hold
Key Takeaways
- Amarin Corporation (AMRN) reported third quarter 2026 total net revenue of $39.6 million, down 20% from $49.7 million in the same period a year earlier.
- The company swung to a net income of $0.2 million, marking its first profitable quarter in more than two years, versus a net loss of $7.7 million in the prior-year period.
- Total operating expenses fell 44% to $18.5 million, reflecting the completed global restructuring and the company's partner-led international commercial model.
- Estimated in-market demand for VASCEPA/VAZKEPA rose 55% across the global partner network, led by 68% growth in Europe under the Recordati partnership.
- Amarin ended the quarter with $323.4 million in cash, cash equivalents, and short-term investments, no debt, and a fourth consecutive quarter of positive free cash flow.
Earnings Context and Why It Matters
For AMRN, the third quarter 2026 report marks a critical checkpoint in the company's multi-year turnaround. After facing generic competition in the United States that steadily eroded revenue, management pivoted to a leaner operating structure and a fully partnered international strategy anchored by its exclusive European agreement with Recordati. The quarter's return to profitability, however modest, signals that the company's cost discipline is beginning to outweigh top-line pressure. In my view, this earnings event offers a window into whether Amarin's restructuring can deliver sustainable cash generation even as U.S. sales of its flagship cardiovascular therapy, VASCEPA (icosapent ethyl, or IPE), continue to face pricing headwinds.
Reported Results
Amarin reported total net revenue of $39.6 million for the third quarter ended September 30, 2026, compared with $49.7 million in the prior-year quarter. Product revenue came in at $36.9 million, while licensing and royalty revenue rose 139% to $2.7 million. U.S. product revenue declined 30% to $28.5 million, reflecting lower net selling prices and customer-mix changes tied to generic IPE competition. European product revenue decreased 9% to $3.7 million, while Rest of World revenue grew 29% to $4.7 million.
The company recorded net income of $0.2 million, its first profitable quarter in over two years, versus a net loss of $7.7 million a year earlier. Total operating expenses fell 44% to $18.5 million, with selling, general, and administrative (SG&A) expenses down 27% and no restructuring charges in the quarter. Amarin held a 47% share of the U.S. IPE market, and management indicated it expects to maintain payer exclusivity through the end of 2026. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and Investor Sentiment
Heading into the report, investor attention was focused on whether Amarin's restructuring would translate into a return to profitability and durable cash generation. The swing to positive net income and a fourth consecutive quarter of positive free cash flow addressed those concerns, reinforcing the narrative that the company has stabilized its balance sheet despite ongoing U.S. revenue declines. At the same time, the continued erosion of U.S. product revenue from generic IPE competition remains a key overhang, and investors are weighing the sustainability of Amarin's cost reductions against a shrinking domestic top line. The strength in international in-market demand, which grew an estimated 55% across the partner network, provided a counterbalance that many analysts viewed favorably.
Forward Outlook and Key Factors to Monitor
Looking ahead, investors should watch several dynamics shaping Amarin's trajectory. First, the durability of U.S. payer exclusivity arrangements will be central, since management expects to maintain these through the end of 2026, but any loss of exclusivity could accelerate price erosion. Second, the pace at which strong international in-market demand converts into recognized product revenue will matter, given the timing lag between patient demand and partner supply orders.
Cost management also remains in focus. With the $70 million annualized savings initiative largely complete, the company now operates with a significantly lower cost base, but gross margin may still vary quarter to quarter based on sales mix and the timing of partner shipments. Management has also flagged renegotiated supply contracts that should gradually lower cost per unit.
On the growth side, upcoming catalysts include planned launches in Singapore and South Korea in early 2027 and continued regulatory and reimbursement progress across Europe through the Recordati partnership. Additionally, updated U.S. and European cardiovascular guidelines that position icosapent ethyl as a proven therapy for reducing cardiovascular events may support longer-term demand, though management notes such effects typically take time to materialize. From what I see, the international momentum is worth monitoring closely here.
Exploring Similar Opportunities with AI Tools
One resource I turn to regularly for this type of analysis is Tickeron’s AI Screener. It helps me filter stocks and ETFs based on technical patterns, fundamentals, trends, and AI-driven signals, making it easier to identify comparable opportunities across the market without manual effort.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
AMRN's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for AMRN turned positive on October 22, 2026. Looking at past instances where AMRN's MACD turned positive, the stock continued to rise in 43 of 55 cases over the following month. The odds of a continued upward trend are 78%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where AMRN's RSI Oscillator exited the oversold zone, 27 of 36 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on AMRN as a result. In 65 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 73%.
Following a +4.22% 3-day Advance, the price is estimated to grow further. Considering data from situations where AMRN advanced for three days, in 184 of 251 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
AMRN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMRN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for AMRN entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 26 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 67 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.569) is normal, around the industry mean (-2.689). P/E Ratio (-9.958) is within average values for comparable stocks, (21.011). Projected Growth (PEG Ratio) (3.220) is also within normal values, averaging (5.738). Dividend Yield (0.000) settles around the average of (0.040) among similar stocks. P/S Ratio (1.554) is also within normal values, averaging (4.033).
The Tickeron Price Growth Rating for this company is 74 (best 1 - 100 worst), indicating slightly worse than average price growth. AMRN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AMRN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biopharmaceutical company, which focuses on commercialization and development of therapeutics to improve cardiovascular health
Industry PharmaceuticalsMajor
Advertisement